Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
-- Subcutaneous Phase 1/2 Proof-of-Concept Clinical Trial of High Potency Factor IX CB 2679d/ISU304 in individuals with Hemophilia B to Commence in the First Quarter of 2017 -- -- Subcutaneous...
-
-- Divestment of Additional Neuronal Nicotinic Receptor Asset to Provide Catalyst with $750,000 Up Front Payment -- -- Catalyst Remains Focused on Improved Factor VIIa and IX Programs to...
-
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biotechnology company focused on creating and developing novel protease...
-
-- Company to Focus on Improved Factor VIIa and IX Programs to Provide Prophylactic Subcutaneous Therapy to Hemophilia Patients -- -- Reduction in Workforce will Reallocate Financial Resources...
-
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), a clinical-stage biotechnology company focused on creating and developing novel protease...
-
-- Phase 1 Proof-of-Concept Clinical Trial of High Potency Factor IX Product Subcutaneous Administration for Hemophilia B to Commence in the First Quarter 2017 -- -- Manufacturing Agreement...
-
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel...
-
-- Divestment of Certain Neuronal Nicotinic Receptor Assets to Provide Catalyst with $1 Million Up Front Payment -- -- Catalyst Remains Focused on Core Therapeutic Areas, Especially Hemophilia -- ...
-
-- Hemostasis patents cover next-generation coagulation factors FVIIa (CB 813d) and FIX (CB 2679d/ISU304) in the United States, Europe and Korea -- -- Anti-complement patent covers novel protease...
-
- Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor VIIa CB 813d -- Catalyst Plans to Initiate Clinical Pivotal Trial in Hemophilia A and B “Inhibitor” Patients...